Cyclin-dependent kinase 2 and Cyclin-dependent kinase 9 (CDK2 and CDK9)

Cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 9 (CDK9) are members of the cyclin-dependent kinase family, which regulate crucial cellular processes. CDK2 is primarily involved in cell cycle control, especially promoting the G1/S phase transition and DNA synthesis, through association with cyclins E and A[1][2][3][4][6]. CDK2’s structure features a bi-lobal fold with a nucleotide-binding cleft and is activated via cyclin binding and phosphorylation of critical residues[1][2][3][5]. CDK2 phosphorylates several cell cycle regulatory proteins, including retinoblastoma protein, driving cell proliferation and participating in DNA replication and repair[4][6][7]. CDK9, while not described in your provided search results, is central in regulating transcriptional elongation by phosphorylating the RNA polymerase II C-terminal domain. Both kinases are considered therapeutic targets in cancer, as deregulation of their activity contributes to oncogenesis and tumor progression. Selective inhibitors of CDK2 and CDK9 are explored in cancer and other diseases, but their use presents challenges due to potential toxicity and the need for selectivity to avoid disrupting normal cellular functions. [Note: Combining CDK2 and CDK9 as a single target entry is technically incorrect, as they are distinct proteins with differing primary biological functions and clinical relevance. Each should ideally be structured as a separate target.]

Other names

Cdk2 (for Cyclin-dependent kinase 2)Cdk9 (for Cyclin-dependent kinase 9)cell division protein kinase 2 (CDK2)CDK-2CDK-9

Inhibition of kinase activity leading to blockade of cell cycle progression (CDK2) or inhibition of transcriptional elongation (CDK9); Induction of apoptosis/cell cycle arrest